Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (8)	12/4/1998 12:25:00 AM
From: Dave K	Respond to of 1833

Hi, Rick. FlatTaxman and I would like to talk to you about settling this alleged '629 patent infringement. Both Cadus and Sibia have dynamite researchers and science. A ruling against us could temporarily set back some very important work. The same can be said for Sibia's position. What do you say you bring your people, we'll bring ours and let's work something out ? Better yet, let's think merger, then we can sue everyone else out here infringing on the patent :-) Seriously, do you know anything about the status of proceedings ? And please no geers or sneers if Sibia wins. We promise not to do the same. Regards Dave

To: scaram(o)uche who wrote (8)	3/30/1999 12:37:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1833

Tuesday March 30, 11:07 am Eastern Time Company Press Release Axiom Biotechnologies Appoints Kevin Mullane, Ph.D. As Executive Vice President, Research SAN DIEGO--(BW HealthWire)--March 30, 1999--Axiom Biotechnologies Inc. today announced that it has appointed Kevin Mullane, Ph.D. to the post of executive vice president, research. Dr. Mullane, who has more than 20 years of pharmaceutical and biotechnology research experience, joins Axiom from Chugai Biopharmaceuticals Inc. where he was senior vice president, research and development. ''We are very pleased to have Kevin join the Axiom management team,'' said Stephen Eisold, Axiom's chief executive officer. ''His 22 years of proven experience in the pharmaceutical and biotechnology industries will provide Axiom with a seasoned manager of internal programs and collaborative research alliances, and a senior scientist with an extensive technical skillset in drug discovery, lead characterization, pharmacological evaluation and pre-clinical development.'' As Senior Vice President, research and development at Chugai Biopharmaceuticals Inc. (CBI) Dr. Mullane was responsible for overseeing strategic R&D directions and implementing a comprehensive drug discovery technology program consisting of high throughput screening, combinatorial chemistry, genomics and bioinformatics platforms. He was also a member of the CBI Board of Directors. Prior to joining CBI, Dr. Mullane spent seven years at Gensia Inc., where he achieved the level of divisional vice president, pharmacology. while at Gensia he was integrally involved with managing research, fundraising and a variety of business development activities, including closing strategic alliances with Marion Merrill Dow and Pfizer Pharmaceuticals. He also was directly involved in the introduction of five new drugs into human clinical trials. Prior to joining Gensia, Dr. Mullane served as director of cardiovascular research at Ciba-Geigy and as research scientist at Wellcome Research Laboratories. He also served for five years as Associate Professor at New York Medical College, department of Pharmacology. Dr. Mullane received his Doctor of Philosophy (Ph.D.) in pharmacology from University of London and his Bachelors of Science Degree in pharmacology from Chelsea College, University of London. Axiom Biotechnologies is a privately-held biotechnology company focused on improving the efficiency of drug discovery by accelerating the process of evolving screening ''hits'' to pre-clinical leads by applying an array of proprietary ''hits''-to-leads technologies and assays. The company's patented flagship technology, the High Throughput Pharmacology System (HT-PS(TM)), combines proprietary natural cell-based assays, high throughput automated instrumentation and novel pharmacoinformatics and biomining tools to assess and prioritize potential lead compounds based on their functional pharmacological properties. Through collaborations with major pharmaceutical companies, Axiom is committed to becoming the pharmaceutical industry's partner of choice in high throughput pharmacology. Contact: Axiom Biotechnologies Inc. Jim Linton, 619/455-4500 www.axiombio.com